Results 241 to 250 of about 82,766 (300)

Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single‐Centre Tertiary Hospital

Australasian Journal on Ageing, Volume 45, Issue 2, June 2026.
ABSTRACT Objective Apixaban is widely recommended as first line therapy for atrial fibrillation (AF) and venous thromboembolism (VTE). Despite the widespread availability of dosing guidelines, anecdotal evidence suggests clinicians do not routinely follow these recommendations. Inappropriate dose reduction is associated with suboptimal patient outcomes.
Katherine J. Creeper, Grace Lenaghan, Aaron Stockwell, Matthew Schmidt, Katharine Ingram, Andrew C. Stafford   +5 more
wiley   +1 more source

Sex‐Specific Associations of Inflammatory Biomarkers With All‐Cause and Cardiovascular Mortality Across Glycaemic Status: A Prospective UK Biobank Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4728-4740, June 2026.
ABSTRACT Aims To explore sex‐specific heterogeneity in the prognostic discrimination of inflammatory markers for mortality across different glycaemic states. Methods This prospective cohort study included 450 438 participants from the UK Biobank (median follow‐up: 15.3 years), stratified by sex and glycaemic status.
Yawen Zhang, Menghan Li, Manrong Xu, Yun Shen, Lianxi Li, Gang Hu   +5 more
wiley   +1 more source

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4975-4990, June 2026.
ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna, Carlos Mena‐Hurtado, Victoria Divino, Zhenxiang Zhao, Yan Chen, Joanna Boland, Jinlin Song, Andrea Traina, Kerem Ozer, Filip K. Knop, Kim G. Smolderen   +10 more
wiley   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 845-849, June 2026.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

G‐CSF for Mobilizing CD34+ Cells in Individuals With SCD: A Word of Caution

American Journal of Hematology, Volume 101, Issue 6, Page 1178-1181, June 2026.
Akshay Sharma, Allistair Abraham, Monica Bhatia, María Cancio, Sonali Chaudhury, Selim Corbacioglu, Gregory M. T. Guilcher, Ashish O. Gupta, Rabi Hanna, Matthew M. Heeney, Tami John, Lakshmanan Krishnamurti, James L. LaBelle, Hemalatha G. Rangarajan, Shalini Shenoy, Elizabeth Stenger, Crawford Strunk, Courtney D. Fitzhugh   +17 more
wiley   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, Volume 116, Issue 6, Page 759-770, June 2026.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

Factors associated with potentially inappropriate medication use, medication underuse and overuse in older adults in the German National Cohort

Journal of Internal Medicine, Volume 299, Issue 6, Page 754-775, June 2026.
Abstract Background Effectively identifying individuals exposed to drug underuse, overuse and potentially inappropriate medication (PIM) in older adults is essential for minimizing preventable drug‐related harms. Methods We analysed data from 54,296 individuals aged 60–74 years from the German National Cohort (NAKO).
Miriam Degen, Ulrike Haug, Oliver H. F. Scholle, Yaw Awuku‐Larbi, Sigrid Carlsson, Nina Ebert, Volker Harth, Anja M. Hauri, Margit Heier, Anne Herrmann, Michael Leitzmann, Jakob Linseisen, Claudia Meinke‐Franze, Nadia Obi, Phil Pendt, Thomas Reinhold, Barbara Thorand, Hermann Brenner, Ben Schöttker   +18 more
wiley   +1 more source

Activated Platelet–Released Heat Shock Protein 90α Triggers Autophagy‐Dependent Neutrophil Extracellular Trap Formation and Amplifies Sepsis

Advanced Science, Volume 13, Issue 25, 4 May 2026.
HSP90α is significantly upregulated in platelets from sepsis patients, with its origin from megakaryocyte‐derived trafficking. Furthermore, activated platelets secrete HSP90α into the extracellular space in both free and exosome‐associated forms. Finally, extracellular HSP90α directly engages TLR4 on neutrophils to induce autophagy, leading to NET ...
Chengbo Wang, Maodong Leng, Chenchen Sun, Jingyu Cao, Linfei Li, Yangyang Jia, Yongshuai Han, Yuchun Liu, Yaodong Zhang, Chenglong Zhang, Yingli Men, Ningyuan Liu, Yibing Cheng, Yixia Zhang, Ya Li, Zhenlong Li, Lidan Cui, Xiangzhan Zhu   +17 more
wiley   +1 more source

Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States

American Journal of Hematology, Volume 101, Issue 5, Page 1005-1018, May 2026.
ABSTRACT Prior epidemiological studies on cancer‐associated venous thromboembolism (VTE) were limited by homogenous patient populations. We leverage Cosmos, a collaborative dataset of Epic electronic health record systems, to conduct an updated evaluation of cancer‐associated VTE in the United States (US).
Barbara D. Lam, Justine Ryu, Omid Jafari, Rock Bum Kim, Shengling Ma, Mrinal Ranjan, Jun Y. Jiang, Ang Li   +7 more
wiley   +1 more source

DNase1 RS1053874 Polymorphism is Associated with Early Neurological Recovery through NET Modulation and with Long‐Term Survival in Ischemic Stroke: A Prospective Cohort Study

Annals of Neurology, Volume 99, Issue 5, Page 1210-1223, May 2026.
Objective Immunothrombosis contributes to ischemic stroke pathophysiology through neutrophil extracellular trap (NET) formation, which promotes thrombus stabilization and microvascular dysfunction. DNase1 is the principal endonuclease responsible for NET degradation.
B. Díaz‐Benito, P. Calleja, L. Alzamora, A. Ruiz‐García, A. Martínez‐Salio, M. Muñoz‐García, F. Ostos, A. García‐Culebras, A. Moraga, M.A. Moro, I. Lizasoain   +10 more
wiley   +1 more source